- Home
- AACG vs ATRA Comparison
AACG vs ATRA Comparison
Compare AACG & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AACG | ATRA |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 38.9M |
| IPO Year | 2008 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AACG | ATRA |
|---|---|---|
| Price | $1.25 | $4.99 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 8.1K | ★ 62.9K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.91 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.74 | $3.92 |
| 52 Week High | $2.58 | $19.15 |
Technical Indicators
Market Signals| Indicator | AACG | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 69.59 | 48.10 |
| Support Level | $1.09 | $4.22 |
| Resistance Level | $1.36 | $5.47 |
| Average True Range (ATR) | 0.10 | 0.39 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 58.18 | 49.67 |
Price Performance
Historical ComparisonAbout AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).